Medtronic has raised its fiscal year 2026 (FY26) profit outlook after the company achieved its strongest cardiovascular portfolio revenue growth in over a decade in Q2. The Ireland-headquartered medtech giant achieved global revenues of almost $9bn in Q2 2026, up 6.6% from the same period in FY25. Medtronic now expects revenue growth for FY26 of 5.5%, an uplift from its prior expectation of 5%. The change relates to a per share price for FY26 of $5.62 to $5.66, up from a prior expectation of $5.60 to $5.6 ...